Pharmacoeconomic review report Dolutegravir (Tivicay)
Dolutegravir (Tivicay) (DTG) is being reviewed as a treatment of HIV in both treatment-naive and treatment-experienced adults and children 12 years of age and older and weighing at least 40 kg, in combination with other antiretrovirals. The recommended oral dose of DTG is 50 mg daily at a daily cost...
| Main Author: | |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | Inglés |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health
2014.
|
| Subjects: | |
| See on Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820270306719 |
| Summary: | Dolutegravir (Tivicay) (DTG) is being reviewed as a treatment of HIV in both treatment-naive and treatment-experienced adults and children 12 years of age and older and weighing at least 40 kg, in combination with other antiretrovirals. The recommended oral dose of DTG is 50 mg daily at a daily cost of 18.50. |
|---|---|
| Physical Description: | 1 online resource (vi, 20 pages) |
